HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Cholesterol Disorders


The Practical Cardiology™ Cholesterol Disorders clinical resource center offers the latest information from the field of lipidology. With hypercholesterolemia and hyperlipidemia representing a crucial aspect of risk management, this page will be a hub for information related to the latest in cholesterol management and dyslipidemia, including articles, videos, and podcasts.

Exposure to Statin Therapy Could Lower Risk of Brain Bleeds in Older Patients

December 09, 2022

Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.

CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events

December 07, 2022

Almost 3 years after approval, Esperion's announcement of positive results from the CLEAR Outcomes trial indicate bempedoic acid is the first oral non-statin therapy to meet the MACE-4 primary endpoint included in the outcomes trial of the ATP citrate lyase inhibitor.

Cardiology Month in Review: November 2022

November 26, 2022

The November 2022 cardiology month in review features the top content from AHA Scientific Sessions 2022, new data related to use of direct oral anticoagulation, and an FDA warning to companies over violations of the FD&C Act.

SPORT: Supplements Fail to Lower LDL-C in Primary Prevention Population

November 08, 2022

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

Ocean(a)-DOSE: Olpasiran Shows Promise for Lowering Lipoprotein(a)

November 06, 2022

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.